Striverdi Respimat

Chemical Nameolodaterol
Dosage FormInhalation spray (oral; 2.5 mcg)
Drug ClassReceptor agonists
SystemRespiratory
CompanyBoehringer Ingelheim
Approval Year2014

Indication

  • For the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Last updated on 7/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Striverdi Respimat (olodaterol) Prescribing Information.2021Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Australian public assessment report for olodaterol. 2014Australian Government: Department of Health